Structural and clinical consequences of activation loop mutations in class III receptor tyrosine kinases

Lillian R. Klug, Jason D. Kent, Michael Heinrich

    Research output: Contribution to journalArticle

    4 Citations (Scopus)

    Abstract

    Mutations within the activation loop of members of the class III receptor tyrosine kinase (RTK) subfamily, which includes KIT, PDGFRA, and FLT3, have been observed in multiple human tumor types. These mutations confer constitutive activation as well as resistance to the type II tyrosine kinase inhibitors (TKI) that are currently clinically available, such as imatinib and sunitinib. It is now understood that activation loop mutations in class III RTKs shift the activation state equilibrium away from inactive states, to which type II TKIs bind, to the active state by destabilizing the inactive conformation. Recently, type I TKIs, which can bind to active kinase conformations, have been developed with specificity for class III RTK members. Some type I TKIs, such as crenolanib and avapritinib (BLU-285), have entered clinical studies for patients with activation loop mutations in KIT, PDGFRA, or FLT3. Preliminary results suggest that these type I TKIs show activity in these patient populations that previously lacked effective treatments. This article reviews the inactive and active structures of KIT, PDGFRA, and FLT3, how the mutations seen in human cancers affect kinase structure, and the clinical implications of these mutations in terms of type I vs. type II TKI binding.

    Original languageEnglish (US)
    JournalPharmacology and Therapeutics
    DOIs
    StateAccepted/In press - Jan 1 2018

    Fingerprint

    Receptor Protein-Tyrosine Kinases
    Mutation
    Protein-Tyrosine Kinases
    Phosphotransferases
    Neoplasms
    Population

    Keywords

    • Activation loop mutation
    • Kinase inhibitor
    • Kinase inhibitor resistance
    • KIT
    • PDGFRA
    • Type I kinase inhibitor

    ASJC Scopus subject areas

    • Pharmacology
    • Pharmacology (medical)

    Cite this

    Structural and clinical consequences of activation loop mutations in class III receptor tyrosine kinases. / Klug, Lillian R.; Kent, Jason D.; Heinrich, Michael.

    In: Pharmacology and Therapeutics, 01.01.2018.

    Research output: Contribution to journalArticle

    @article{81e7ba9ddbbc4e749b0e241a6bb9a6ee,
    title = "Structural and clinical consequences of activation loop mutations in class III receptor tyrosine kinases",
    abstract = "Mutations within the activation loop of members of the class III receptor tyrosine kinase (RTK) subfamily, which includes KIT, PDGFRA, and FLT3, have been observed in multiple human tumor types. These mutations confer constitutive activation as well as resistance to the type II tyrosine kinase inhibitors (TKI) that are currently clinically available, such as imatinib and sunitinib. It is now understood that activation loop mutations in class III RTKs shift the activation state equilibrium away from inactive states, to which type II TKIs bind, to the active state by destabilizing the inactive conformation. Recently, type I TKIs, which can bind to active kinase conformations, have been developed with specificity for class III RTK members. Some type I TKIs, such as crenolanib and avapritinib (BLU-285), have entered clinical studies for patients with activation loop mutations in KIT, PDGFRA, or FLT3. Preliminary results suggest that these type I TKIs show activity in these patient populations that previously lacked effective treatments. This article reviews the inactive and active structures of KIT, PDGFRA, and FLT3, how the mutations seen in human cancers affect kinase structure, and the clinical implications of these mutations in terms of type I vs. type II TKI binding.",
    keywords = "Activation loop mutation, Kinase inhibitor, Kinase inhibitor resistance, KIT, PDGFRA, Type I kinase inhibitor",
    author = "Klug, {Lillian R.} and Kent, {Jason D.} and Michael Heinrich",
    year = "2018",
    month = "1",
    day = "1",
    doi = "10.1016/j.pharmthera.2018.06.016",
    language = "English (US)",
    journal = "Pharmacology and Therapeutics",
    issn = "0163-7258",
    publisher = "Elsevier Inc.",

    }

    TY - JOUR

    T1 - Structural and clinical consequences of activation loop mutations in class III receptor tyrosine kinases

    AU - Klug, Lillian R.

    AU - Kent, Jason D.

    AU - Heinrich, Michael

    PY - 2018/1/1

    Y1 - 2018/1/1

    N2 - Mutations within the activation loop of members of the class III receptor tyrosine kinase (RTK) subfamily, which includes KIT, PDGFRA, and FLT3, have been observed in multiple human tumor types. These mutations confer constitutive activation as well as resistance to the type II tyrosine kinase inhibitors (TKI) that are currently clinically available, such as imatinib and sunitinib. It is now understood that activation loop mutations in class III RTKs shift the activation state equilibrium away from inactive states, to which type II TKIs bind, to the active state by destabilizing the inactive conformation. Recently, type I TKIs, which can bind to active kinase conformations, have been developed with specificity for class III RTK members. Some type I TKIs, such as crenolanib and avapritinib (BLU-285), have entered clinical studies for patients with activation loop mutations in KIT, PDGFRA, or FLT3. Preliminary results suggest that these type I TKIs show activity in these patient populations that previously lacked effective treatments. This article reviews the inactive and active structures of KIT, PDGFRA, and FLT3, how the mutations seen in human cancers affect kinase structure, and the clinical implications of these mutations in terms of type I vs. type II TKI binding.

    AB - Mutations within the activation loop of members of the class III receptor tyrosine kinase (RTK) subfamily, which includes KIT, PDGFRA, and FLT3, have been observed in multiple human tumor types. These mutations confer constitutive activation as well as resistance to the type II tyrosine kinase inhibitors (TKI) that are currently clinically available, such as imatinib and sunitinib. It is now understood that activation loop mutations in class III RTKs shift the activation state equilibrium away from inactive states, to which type II TKIs bind, to the active state by destabilizing the inactive conformation. Recently, type I TKIs, which can bind to active kinase conformations, have been developed with specificity for class III RTK members. Some type I TKIs, such as crenolanib and avapritinib (BLU-285), have entered clinical studies for patients with activation loop mutations in KIT, PDGFRA, or FLT3. Preliminary results suggest that these type I TKIs show activity in these patient populations that previously lacked effective treatments. This article reviews the inactive and active structures of KIT, PDGFRA, and FLT3, how the mutations seen in human cancers affect kinase structure, and the clinical implications of these mutations in terms of type I vs. type II TKI binding.

    KW - Activation loop mutation

    KW - Kinase inhibitor

    KW - Kinase inhibitor resistance

    KW - KIT

    KW - PDGFRA

    KW - Type I kinase inhibitor

    UR - http://www.scopus.com/inward/record.url?scp=85049335367&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=85049335367&partnerID=8YFLogxK

    U2 - 10.1016/j.pharmthera.2018.06.016

    DO - 10.1016/j.pharmthera.2018.06.016

    M3 - Article

    C2 - 29964125

    AN - SCOPUS:85049335367

    JO - Pharmacology and Therapeutics

    JF - Pharmacology and Therapeutics

    SN - 0163-7258

    ER -